Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/pilot-experience-with-continuous-infusion-alemtuzumab-in-patients-with-VbjMlemp0v
References (10)
-
P. Rebello, G. Hale (2002)
Pharmacokinetics of CAMPATH-1H: assay development and validation.Journal of immunological methods, 260 1-2
-
W. Rowan, J. Tite, P. Topley, S. Brett (1998)
Cross‐linking of the CAMPATH‐1 antigen (CD52) mediates growth inhibition in human B‐ and T‐lymphoma cell lines, and subsequent emergence of CD52‐deficient cellsImmunology, 95
-
(1999)
Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas -
G. Hale, P. Rebello, L. Brettman, C. Fegan, B. Kennedy, E. Kimby, M. Leach, J. Lundin, H. Mellstedt, P. Moreton, A. Rawstron, H. Waldmann, A. Osterborg, P. Hillmen (2004)
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.Blood, 104 4
-
M. Keating, I. Flinn, V. Jain, J. Binet, P. Hillmen, J. Byrd, M. Albitar, L. Brettman, P. Santabarbara, B. Wacker, K. Rai (2002)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.Blood, 99 10
-
A. Ferrajoli, S. O'brien, J. Cortes, F. Giles, D. Thomas, S. Faderl, R. Kurzrock, S. Lerner, D. Kontoyiannis, M. Keating (2003)
Phase II study of alemtuzumab in chronic lymphoproliferative disordersCancer, 98
-
S. Tang, K. Hewitt, M. Reis, N. Berinstein (1996)
Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma.Leukemia & lymphoma, 24 1-2
-
M. Keating, S. O'brien, D. Kontoyiannis, W. Plunkett, C. Koller, M. Beran, S. Lerner, H. Kantarjian (2002)
Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 43
-
J. Isaacs, V. Manna, N. Rapson, K. Bulpitt, B. Hazleman, E. Matteson, E. Clair, T. Schnitzer, J. Johnston (1996)
CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.British journal of rheumatology, 35 3
-
Geoffrey Hale, M. Xia, H. Tighe, Martin Dyer, H. Waldmann (1990)
The CAMPATH-1 antigen (CDw52).Tissue antigens, 35 3
- Publisher
- Wiley
- Copyright
- © 2008 The Authors
- ISSN
- 0902-4441
- eISSN
- 1600-0609
- DOI
- 10.1111/j.1600-0609.2007.01023.x
- pmid
- 18182081
- Publisher site
- See Article on Publisher Site
Abstract
We evaluated the activity and tolerability of alemtuzumab given as a continuous infusion for 7 d followed by subcutaneous administration for 11 wk as salvage therapy for 10 patients with fludarabine‐refractory chronic lymphocytic leukemia. The continuous infusion of alemtuzumab was well tolerated. The typical infusion reaction seen with intravenous alemtuzumab was abolished. Two patients achieved a partial response with an overall response rate of 20%. Alemtuzumab levels were measured in four patients and detectable levels were obtained in three. Clinical activity needs to be confirmed in a larger patient population.
Journal
European Journal of Haematology – Wiley
Published: Apr 1, 2008